Clinical Fellowship Program

Training Movement Disorder Specialists

Dystonia is a multifaceted neurological disorder.  Despite advances in clinical management and  research, the diagnosis of dystonia continues to be, far too often, delayed or missed. Although treatment options have expanded with the recent approval of botulinum neurotoxins and the success of deep brain stimulation, patients with dystonia continue to report difficulties in locating physicians who know how to evaluate their individual needs and to develop an appropriate treatment plan. In addition, there is a great need for better understanding of the disorder in its various clinical manifestations and for the development of better treatments.  This emphasizes the urgent need for training more experts in dystonia, which can be best achieved by additional fellowship training in movement disorders with special emphasis on dystonia.

DMRF is pleased to offer one-year clinical fellowships to support the training of  exceptionally qualified physicians in preparation for their clinical and/or research career in movement disorders with emphasis on dystonia and a special competence in use of botulinum toxins.

In 2022, this program will support fellows through grants to the DMRF from Ipsen Biopharmaceuticals and Merz Therapeutics.

The fellowship should focus on training in both the clinical evaluation and care of patients with dystonia and the conduct of clinical research on dystonia.  The training must be patient-oriented and include hands-on experience in clinics as well as participation in professional meetings and workshops. Involvement in the activities of the Dystonia Coalition will also be expected.

Applicants must be board certified or board eligible in neurology, have completed a neurology residency, hold a license to practice medicine in the United States, and intend to practice in the US upon the completion of their fellowship.

The fellowships will be awarded to first, second, or third year movement disorder fellows who can directly engage in dystonia research at institutions with established training programs that have the appropriate resources to provide both clinical and research training in dystonia, including the use of all botulinum toxin type A and type B approved for use in the United States.  The applicant must have a mentor at the institution with clinical expertise in dystonia, who will develop a mentorship plan for the fellow. To become eligible, an institution must provide information on the training environment, program curriculum, available resources and the expected amount of exposure to patients with dystonia. Fellows are expected to prioritize their dystonia research and seize every opportunity to focus their clinical time with dystonia patients.

Applications for the fellowships, which are expected to start July 1, 2022, should be submitted electronically to the DMRF by January 7, 2022.

Each fellow will receive a stipend in the amount of $65,000 per year.  Up to 10% ($6,500) of the award may be used by the fellow for research expenses and travel to scientific and clinical meetings. No institutional indirect cost is allowed. The fellowship is for only one year and is not renewable.  Previous awardees are not eligible to apply.

Applications for the fellowships, which are expected to start July 1, 2022, should be submitted electronically to the DMRF by January 7, 2022.

For further information and application materials please contact with subject Clinical Fellowship.

Dystonia Community

How You Can Help